November 2014

New Product - Misodel

Misodel (misoprostol) is a synthetic analogue of prostaglandin E1 (PGE1), a naturally occurring oxytocic compound. Misodel is indicated for the induction of labour in women with an unfavourable cervix, from 36 weeks gestation in whom induction is clinically indicated and in a hospital where continuous electronic foetal monitoring is available. Misodel is contraindicated in each of the following conditions. When labour has started; in hospitals where it is not possible to institute continuous electronic foetal heart monitoring; when there is suspicion or evidence of foetal compromise before induction (e.g. failed non-stress or stress test, meconium staining or diagnosis or history of non-reassuring foetal status); when the patient is already receiving oxytocic drugs or other labour induction agents; when there is suspicion or evidence of uterine scar resulting from previous uterine or cervical surgery (e.g. Caesarean section); when there is uterine abnormality (e.g. bicornate uterus); when there is placenta praevia or unexplained vaginal bleeding after 24 weeks gestation with this pregnancy; when there is foetal malpresentation; when there are signs or symptoms of chorioamnionitis, unless adequate prior treatment has been instituted; foetal macrosomia; oligohydramnios; multiple foetuses; in women who have had more than 3 previous vaginal deliveries after 24 weeks gestation (Misodel has not been studied); before 36 completed weeks gestation; and where there is hypersensitivity to the active substance or to any of the excipients. Misodel is available as a 200 microgram pessary in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629